会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Methods of treating patients suffering from movement disorders
    • 治疗运动障碍患者的方法
    • US07727994B2
    • 2010-06-01
    • US11326516
    • 2006-01-06
    • Hiroshi KaseAkihisa MoriYutaka WakiYutaka OhsawaAkira KarasawaYoshihisa Kuwana
    • Hiroshi KaseAkihisa MoriYutaka WakiYutaka OhsawaAkira KarasawaYoshihisa Kuwana
    • A61K31/522A61K31/505
    • A61K31/522A61K9/0019A61K9/20A61K9/48A61K31/198A61K45/06
    • The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
    • 本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。 本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。 本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合(即L-DOPA备用效应)来治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物, 。 本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂,L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。 本发明还提供了延长帕金森病有效治疗的方法,通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A2A受体拮抗剂,而无需先前或随后给予L-DOPA ,延迟或消除L-DOPA电机并发症。
    • 3. 发明授权
    • Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy
    • 管理腺苷A2A受体拮抗剂以减少或抑制帕金森病治疗的副作用
    • US07727993B2
    • 2010-06-01
    • US11326414
    • 2006-01-06
    • Hiroshi KaseAkihisa MoriYutaka WakiYutaka OhsawaAkira KarasawaYoshihisa Kuwana
    • Hiroshi KaseAkihisa MoriYutaka WakiYutaka OhsawaAkira KarasawaYoshihisa Kuwana
    • A61K31/522A61K31/505
    • A61K31/522A61K9/0019A61K9/20A61K9/48A61K31/198A61K45/06
    • The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
    • 本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。 本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。 本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合(即L-DOPA备用效应)来治疗具有亚临床有效剂量的L-DOPA的帕金森病患者的方法和组合物, 。 本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂,L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。 本发明还提供了延长帕金森病有效治疗的方法,通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A2A受体拮抗剂,而无需先前或随后给予L-DOPA ,延迟或消除L-DOPA电机并发症。
    • 4. 发明申请
    • Methods of treating patients suffering from movement disorders
    • 治疗运动障碍患者的方法
    • US20060148827A1
    • 2006-07-06
    • US11326516
    • 2006-01-06
    • Hiroshi KaseAkihisa MoriYutaka WakiYutaka OhsawaAkira KarasawaYoshihisa Kuwana
    • Hiroshi KaseAkihisa MoriYutaka WakiYutaka OhsawaAkira KarasawaYoshihisa Kuwana
    • A61K31/522A61K31/198A61K31/137
    • A61K31/522A61K9/0019A61K9/20A61K9/48A61K31/198A61K45/06
    • The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
    • 本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A 2受体拮抗剂来治疗运动障碍的方法。 本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。 本发明进一步提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合(用于治疗患有亚临床有效剂量的L-DOPA)的帕金森病患者的方法和组合物 即L-DOPA保护作用)。 本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂,L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO来有效治疗帕金森病的方法 抑制剂。 本发明还提供了通过单独或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用腺苷A 2A受体拮抗剂而延长帕金森病有效治疗的方法,而没有 之前或之后的L-DOPA给药,延迟或去除L-DOPA运动并发症。